Grant: Proof of Principle Program - Phase I
Université Laval
$142,600.00
Development of anti-S100 proteins for the treatment of arthritis
EF 2009-10
Résumé
For the last ten years, we have been studying the novel cytokines S100A8, S100A9, and S100A12. We recently demonstrated that inhibition of these cytokines leads to reduced inflammation in a model of gouty arthritis. Interestingly, massive levels of S100A8/A9 are observed in the feces and serum of patients who have Crohn disease and ulcerative colitis, as well as in the synovial fluid and serum of patients with gouty, psoriasis and rheumatoid arthritis.Thus, S100A8 and S100A9 represent interesting drug targets for the development of anti-inflammatory drugs. Patents claiming a method of treatment of inflammatory reactions using an anti-S100A8 and/or an anti-S100A9 were recently granted to us in the USA (US20050288211, but restricted to gout) and Europe (EP1519749).The present grant application is aimed at demonstrating the efficacy of anti-S100A8 and anti-S100A9 in a mouse model of rheumatoid arthritis. If successful, the planned experiments will extend the potential use of inhibitors of S100A8 and S100A9 from gouty arthritis to another arthritic disease, namely rheumatoid arthritis. This will greatly increase the appeal of the technology and facilitate the transfer of the technology.
Programme
Proof of Principle Program - Phase I
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
184783
Name
Tessier Philippe A
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Musculoskeletal Health and Arthritis
Theme2
Biomedical
Prcname2
Proof of Principle
Projecttitle
Development of anti-S100 proteins for the treatment of arthritis
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$142,600
Cihrequipment2
$0
Programname2
Proof of Principle Program - Phase I
Keyworddelim
Arthritis; Elisas; In Vivo Models; Inflammation
Abstract
For the last ten years, we have been studying the novel cytokines S100A8, S100A9, and S100A12. We recently demonstrated that inhibition of these cytokines leads to reduced inflammation in a model of gouty arthritis. Interestingly, massive levels of S100A8/A9 are observed in the feces and serum of patients who have Crohn disease and ulcerative colitis, as well as in the synovial fluid and serum of patients with gouty, psoriasis and rheumatoid arthritis.Thus, S100A8 and S100A9 represent interesting drug targets for the development of anti-inflammatory drugs. Patents claiming a method of treatment of inflammatory reactions using an anti-S100A8 and/or an anti-S100A9 were recently granted to us in the USA (US20050288211, but restricted to gout) and Europe (EP1519749).The present grant application is aimed at demonstrating the efficacy of anti-S100A8 and anti-S100A9 in a mouse model of rheumatoid arthritis. If successful, the planned experiments will extend the potential use of inhibitors of S100A8 and S100A9 from gouty arthritis to another arthritic disease, namely rheumatoid arthritis. This will greatly increase the appeal of the technology and facilitate the transfer of the technology.
Competitiondate
200904
Approvedterm2
1 yr 0 mth
Pinamesdelim
Tessier, Philippe A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $142,600~ $0~